Hi from #ASCO18 !

Abscopal effect of radiotherapy combined with immune checkpoint inhibitors Journal of Hematology & Oncology201811:104

Cytokine release syndrome: grading, modeling, and new therapy jhoonline.biomedcentral.com/articles/10.11…

Organoid technology and applications in cancer research jhoonline.biomedcentral.com/articles/10.11…

Daratumumab safe on mobilized CD34+ cells of myeloma patients in… biomedcentral.altmetric.com/details/498431…

Platelets are increasingly known to be involved in carcinogenesis and metastasis!!! Role of platelets and platelet receptors in cancer metastasis jhoonline.biomedcentral.com/articles/10.11…

Cytokine release syndrome: grading, modeling, and new therapy jhoonline.biomedcentral.com/articles/10.11…. Anti-IL1R therapy looks promising for CRS/CRES prevention and therapy. Clinical trials are coming! Separation of CRS and CART cell function --another major finding! Trials underway!

Universal CARs, universal T cells, and universal CAR T cells jhoonline.biomedcentral.com/articles/10.11…

Siglec-15 was disclosed in this update meeting and data just published in Cell by Lieping Chen. Recent updates in cancer immunotherapy: a comprehensive review and perspective of the 2018 China Cancer Immunotherapy Workshop in Beijing jhoonline.biomedcentral.com/articles/10.11…

This was presented at ASCO and ASH, data finally published!!! A phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or refractory multiple myeloma jhoonline.biomedcentral.com/articles/10.11…

What does Lunar New Year mean to you? - South China Morning Post apple.news/ADWnDehGIQaGOC…

The first PD-1 antibody originated from China got approved in CHina. Safety and clinical activity with an anti-PD-1 antibody JS001 in advanced melanoma or urologic cancer patients jhoonline.biomedcentral.com/articles/10.11…

miniHCVD-INO-blinatumomab will be a key regimen for ALL therapy!!! Clinical trial update on bispecific antibodies, antibody-drug conjugates, and antibody-containing regimens for acute lymphoblastic leukemia jhoonline.biomedcentral.com/articles/10.11…

miniHCVD-INO-blinatumomab regimen for acute lymphoblastic leukemia. doi.org/10.1186/s13045…

Universal CAR T trials, PALL and CALM, revealed very mild GVHD (grade I). doi.org/10.1186/s13045…

ScienceTake | Ice Fish Don’t Melt nyti.ms/2NDWzNX via New York Times Video

x.com/FoundationToc/…

New article: Novel agents and regimens for hematological malignancies: recent updates from 2020 ASH annual meeting link.paperbirds.me/RyJKV0 #MMSM #MultipleMyeloma #hematology

We extend our heartfelt thanks to all the dedicated professionals who contributed to the success of the 11th New York Oncology Forum! Your insights and collaboration are advancing cancer care and fostering innovation. Together, we’re pushing boundaries, strengthening